UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Annals of oncology, 2021-06, Vol.32 (6), p.757-765

2021

Volltextzugriff (PDF)

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

Annals of oncology, 2008-08, Vol.19 (8), p.1387-1392

2008

Volltextzugriff (PDF)

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

The New England journal of medicine, 2023-12, Vol.389 (23), p.2162-2174

2023

Volltextzugriff (PDF)

Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

Gynecologic oncology, 2018-06, Vol.149, p.38-38

2018

Volltextzugriff (PDF)

The Role of Topotecan in the Treatment of Brain Metastases

The oncologist (Dayton, Ohio), 2004-02, Vol.9 (1), p.68-79

2004

Volltextzugriff (PDF)

Patient Preference for Tivozanib Hydrochloride or Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Taurus Study

Annals of oncology, 2012-09, Vol.23, p.ix293

2012

Volltextzugriff (PDF)

Advances in the management of epithelial ovarian cancer

Journal of reproductive medicine, 2005-06, Vol.50 (6), p.426

2005

Volltextzugriff (PDF)

7113 Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus

European journal of cancer supplements, 2009, Vol.7 (2), p.426-427

2009

Volltextzugriff (PDF)

Tivozanib Pharmacokinetic (PK)/Pharmacodynamic (PD) Analysis of Blood Pressure (BP) and Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2) in Patients with Advanced Renal Cell Carcinoma (RCC)

Annals of oncology, 2012-09, Vol.23, p.ix263

2012

Volltextzugriff (PDF)

Population pharmacokinetic modeling for intravenous temsirolimus and sirolimus metabolite in subjects with various solid tumors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.2522-2522

2009

Volltextzugriff (PDF)

4011 POSTER Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-a or the combination of temsirolimus + interferon-a

European journal of cancer supplements, 2007, Vol.5 (4), p.282-283

2007

Volltextzugriff (PDF)

Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3027-3027

2011

Volltextzugriff (PDF)

Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.9541-9541

2010

Volltextzugriff (PDF)

Abstract P3-14-05: Safety and Efficacy of Neratinib (HKI-272) Plus Vinorelbine in the Treatment of Patients with ErbB2+ Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P3-P3-14-05

2010

Volltextzugriff (PDF)

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer

Gynecologic oncology, 2004-12, Vol.95 (3), p.624-631

2004

Volltextzugriff (PDF)

P040 Tivozanib pharmacokinetic (PK)/pharmacodynamic (PD) analysis of blood pressure (BP) and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma (RCC)

European urology supplements : official journal of the European Association of Urology, 2012-11, Vol.11 (5), p.203-204

2012

Volltextzugriff (PDF)

A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS137-TPS137

2011

Volltextzugriff (PDF)

Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5116-5116

2008

Volltextzugriff (PDF)

Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5050-5050

2008

Volltextzugriff (PDF)

Phase II trial of capecitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14103-14103

2006

Volltextzugriff (PDF)

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

European urology supplements : official journal of the European Association of Urology, 2012-11, Vol.11 (5), p.185-185

2012

Volltextzugriff (PDF)

Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5033-5033

2007

Volltextzugriff (PDF)

Phase II trial of GM-CSF in women with asymptomatic müllerian cancer

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.5081-5081

2006

Volltextzugriff (PDF)

STA-4783, a novel HSP inducer, enhances paclitaxel activity—Preclinical to clinical modeling

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3124-3124

2004

Volltextzugriff (PDF)

STA-4783, a novel HSP inducer, enhances paclitaxel activity—Preclinical to clinical modeling

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3124-3124

2004

Volltextzugriff (PDF)

1 – 25 von 188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(141)

Publikationsform

Sprache

Englisch
(187)
Japanisch
(11)
Russisch
(2)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

The Role of Topotecan in the Treatment of Brain Metastases

Patient Preference for Tivozanib Hydrochloride or Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Taurus Study

Advances in the management of epithelial ovarian cancer

7113 Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus

Tivozanib Pharmacokinetic (PK)/Pharmacodynamic (PD) Analysis of Blood Pressure (BP) and Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2) in Patients with Advanced Renal Cell Carcinoma (RCC)

Population pharmacokinetic modeling for intravenous temsirolimus and sirolimus metabolite in subjects with various solid tumors

4011 POSTER Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-a or the combination of temsirolimus + interferon-a

Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors

Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma

Abstract P3-14-05: Safety and Efficacy of Neratinib (HKI-272) Plus Vinorelbine in the Treatment of Patients with ErbB2+ Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer

P040 Tivozanib pharmacokinetic (PK)/pharmacodynamic (PD) analysis of blood pressure (BP) and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma (RCC)

A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC)

Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α

Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features

Phase II trial of capecitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN)

Phase II trial of GM-CSF in women with asymptomatic müllerian cancer

STA-4783, a novel HSP inducer, enhances paclitaxel activity—Preclinical to clinical modeling

STA-4783, a novel HSP inducer, enhances paclitaxel activity—Preclinical to clinical modeling

Suchergebnisse filtern